Neurocrine Acquires Soleno
Neurocrine Acquires Soleno to add VYKAT XR and strengthen its first-in-class rare-disease lineup; the $53 per share deal prompted split share reactions.
KEY TAKEAWAYS
- Neurocrine will pay $53 per share in cash, valuing Soleno at $2.9 billion.
- The deal adds VYKAT XR, the first FDA-approved hyperphagia therapy for Prader-Willi syndrome, with IP into mid-2040s.
- Post-transaction portfolio will include three first-in-class medicines, strengthening Neurocrine's commercial runway.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Neurocrine Biosciences (NBIX) said in a joint press release on April 6, 2026, that it will acquire Soleno Therapeutics (SLNO), adding VYKAT XR, an FDA-approved therapy for hyperphagia in Prader-Willi syndrome, and expanding its first-in-class commercial portfolio.
Deal Terms and Strategic Rationale
Neurocrine will pay $53.00 a share in cash, valuing Soleno’s equity at $2.9 billion, according to the joint release. This price exceeds earlier reports that suggested a deal near $2.5 billion and in the low-to-mid $50s per share.
The acquisition adds VYKAT XR (diazoxide choline), the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine’s endocrinology and rare-disease franchise. The therapy’s intellectual property protection extends into the mid-2040s, strengthening Neurocrine’s commercial lineup.
Post-transaction, Neurocrine’s portfolio will include three first-in-class medicines: INGREZZA (valbenazine), CRENESSITY (crinecerfont), and VYKAT XR. The companies described the deal as establishing a durable platform for long-term revenue growth and value creation based on these assets and the extended IP estate.
Share Reaction and Market Context
The companies announced the definitive agreement in a joint press release. Soleno’s shares rose in premarket trading following reports of the acquisition, while Neurocrine’s stock declined after the announcement.
Earlier reports had placed a potential deal near $2.5 billion and in the low-to-mid $50s per share, below the confirmed price. The divergence in share movements reflected market reaction to the finalized terms.
